Reims

• IntReALL BCP 2020 – International Study for Treatment of Childhood Relapsed Precursor B-cell ALL 2020 Pending
  2023-509392-17-00 5 Relapsed Acute Lymphoblastic Leukemia (ALL)
• SEMAFORCRANIO : Multicenter, double-blind, parallel, randomized controlled trial of the efficacy of semaglutide in hypothalamic obesity seco … Pending
  2024-511114-20-00 5 Craniopharyngioma
• CAALL-F01: a French protocol for the treatment of acute lymphoblastic leukemia (ALL) in children and adolescents Pending
  2024-514243-29-01 5 This is a prospective, French, multicenter, open-label, design, strati
• LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy Pending
  2024-515340-23-00 4 Colon cancer
• LEvOsimendaN vs. Placebo Before Tricuspid VAlve Surgery in Patients with Right Ventricular Dysfunction Pending
  2024-516167-86-00 5 Patients referred for an isolated or a combined surgical correction of
• “Intravenous Thrombolysis With Tenecteplase Plus Thrombectomy Versus Thrombectomy Alone In Patients With A Large Ischemic Stroke: A Multicen … Pending
  2024-520414-21-00 5 Adult patients with a LVOS with large core within 9 hours of symptoms
• Evaluation of the efficacy and safety of bimekizumab (BZK) or adalimumab (ADA) in the treatment of anterior chest wall pain associated with … Pending
  2025-520632-42-00 5 axial or predominantly axial SpA with or without psoriasis
• PALETTE - Trial for personalisation of sepsis treatment in children and adults Pending
  2025-521371-31-00 4 Sepsis
• Study evaluating two treatment strategies for rectal cancer in patients ≥75 years old Pending
  2025-521619-37-00 5 Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to r
• Personnalized immunotherapy in patients with stage III non-small cell lung cancer Pending
  2025-522801-39-00 4 Stage III Non Small Cell Lung Cancer
• Upadacitinib in adult patients with erosive mucosal Lichen Planus and Lichen Planopilaris. Pending
  2025-522870-35-00 4 Lichen
• Effects of butyrate enemas on postoperative intestinal motility disorders in Hirschsprung’s disease Pending
  2025-523094-42-00 5 Hirschsprung's disease
• A Phase 3 extension study to assess the long-term safety and efficacy of remibrutinib in adult participants with moderate to severe hidraden … Pending
  2025-523259-72-00 5 Hidradenitis Suppurativa (HS)
• TAILORswitch (PADA-2): rising ctDNA to tailor endocrine therapy switch in patients with ER+/HER2- metastatic breast cancer. Pending
  2025-524213-84-00 5 Patients with advanced or metastatic ER+ HER2- breast cancer
• Real-world study to evaluate how effective and safe Pegcetacoplan is in patients with rare kidney diseases called C3G or IC-MPGN in multiple … Pending
  2025-524487-37-00 6 Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MP
• A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Recruiting
  2025-523586-18-00 5 2026-06-11 Non-Small Cell Lung Cancer
• Phase III randomized international open label clinical trial of treatment Intensification with docetaxel plus apalutamide in patients with m … Recruiting
  2025-524408-30-01 5 2026-06-05 Metastatic hormone-sensitive prostate cancer
• Screening for subclinical antibody mediated rejection and efficacy of belatacept in the context of de novo donor specific antibody after kid … Recruiting
  2024-516527-13-00 11 2026-05-27 Kidney transplantation
• Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Recruiting
  2024-519655-28-00 5 2026-04-23 Premenopausal patients with high-risk HR-positive/HER2-negative breast
• Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( R … Recruiting
  2024-519818-31-01 5 2026-04-10 Endometrial Cancer Advanced, Recurrent, Metastatic, or Primary Unresec
• NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting
  2025-520979-13-00 5 2025-12-18 Patients with HR+ HER2- early breast cancer at intermediate risk of re
• Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC. Recruiting
  2024-516906-47-00 10 2025-11-28 Locally Advanced or Metastatic Urothelial Carcinoma
• Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting
  2024-520107-12-00 5 2025-09-03 Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C … Recruiting
  2024-515445-42-00 5 2025-03-24 Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast

Showing 1–24 of 208 trials